Cyted Health, a British gastrointestinal (GI) molecular diagnostics company, announced this weekend a first close of €37.5 million in its Series B financing round to accelerate its ongoing US expansion.
The round was led by EQT Life Sciences, investing through its EQT Health Economics strategy, and co-led by Advent Life Sciences and British Business Bank with continued support from existing investors Morningside and BGF.
“This Series B financing marks a defining moment for Cyted as we continue to deepen our commitment to detecting esophageal diseases earlier,” said Marcel Gehrung, CEO and Co-founder of Cyted Health. “This investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio.”
Founded in 2020, Cyted Health is a gastrointestinal molecular diagnostics company dedicated to improving early detection and prevention of esophageal adenocarcinoma through innovative, minimally invasive diagnostics. The company has built a portfolio of peer-reviewed publications, conducted over 35,000 tests using its diagnostic platform, and is used across the National Health Service in the UK.
Founded by experts at the University of Cambridge, Cyted is pioneering the development of minimally invasive cell collection coupled with proprietary biomarker discovery to transform the detection of pre-cancerous, cancerous and inflammatory esophageal conditions.
Science Minister Lord Vallance said: “I am pleased to see the British Business Bank back Cyted – a company whose growth demonstrates the ability of our universities to turn world-class life sciences research into successful commercial opportunities with the potential to improve people’s lives. Life sciences form a critical part of this Government’s ambitions for both the economy and healthcare – and through our Life Sciences Sector Plan, we will continue to support the industry to even greater success.”
Cyted’s Series B financing round follows the recent launch of Cyted’s DETECT-ME clinical validation study, which has been enrolling patients across multiple sites in the US since March 2025.
This study will validate clinical performance of Cyted’s newest assays and molecular tests for the detection of esophageal conditions using EndoSign, an FDA 510(k)-cleared device enabling minimally invasive collection of esophageal cells, and advanced biomarker molecular testing for the detection of esophageal conditions.
Bruno Holthof, Partner at EQT Life Sciences, commented: “Cyted is strongly positioned to redefine the standard of care in upper GI diagnostics worldwide. Its minimally invasive diagnostics platform is the standout innovation to capture this significant market opportunity, and we’re delighted to add the company to our portfolio.”
The financing will be used to accelerate the commercial expansion of Cyted’s diagnostics platform in the US, consolidate existing commercial success across the UK, and expand its portfolio of advanced diagnostic tests.
Esophageal cancer is considered one of the deadliest cancers globally, with a survival rate of only 20%.
Carmine Circelli, Director, Life Sciences at British Business Bank, added: “Cyted is an excellent example of the kind of high-impact business we aim to back. Their innovation has the potential to transform early cancer detection and create lasting health outcomes both in the UK and globally.”
Read the orginal article: https://www.eu-startups.com/2025/09/cambriges-cyted-health-raises-over-e37-million-to-improve-early-detection-and-prevention-of-esophageal-adenocarcinoma/
